An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases

2006280 citationsJournal Article

Authors

SU11248 is a highly effective tyrosine kinase inhibitor of the RET/PTC oncogenic kinase.

Good health and well-being

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 91, Issue 10, pp. 4070-4076

Field-Weighted Citation Impact: 15.73